Abstract: The artificial pancreas (AP) is a set of increasingly sophisticated devices and algorithms that will automate the delivery of insulin to patients with type-­‐1 diabetes. While the AP concept promises to alleviate the burden posed by the self-­‐ management of blood glucose levels, it also poses significant risks arising from a combination of external disturbances such as patient meals, physical activity, sensor errors, network delays and physiological variations.